Disease Domain | Count |
---|---|
Infectious Diseases | 4 |
Nervous System Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Chemical drugs | 1 |
Synthetic peptide | 1 |
Top 5 Target | Count |
---|---|
CYP51A1(Cytochrome P450 51) | 1 |
Peptidoglycan | 1 |
Target- |
Mechanism Cell membrane function inhibitors |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date12 Sep 2003 |
Target |
Mechanism CYP51A1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date19 Mar 2002 |
Target |
Mechanism Peptidoglycan inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date01 Jan 1954 |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Vancomycin Hydrochloride ( Peptidoglycan ) | Bone and joint infections More | Approved |
Voriconazole ( CYP51A1 ) | Systemic Candidiasis More | Approved |
Daptomycin | Complicated skin and skin structure infection More | Approved |
XEL-1015 | Gram-Positive Bacterial Infections More | Preclinical |
XEL-1000 | Respiratory Tract Infections More | Pending |